Menu
Back to Journals » Psoriasis: Targets and Therapy » Volume 12
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management [Corrigendum]
Authors Al-Janabi A, Yiu ZZN
Received 29 June 2022
Accepted for publication 29 June 2022
Published 1 July 2022 Volume 2022:12 Pages 187—188
Al-Janabi A, Yiu ZZN. Psoriasis (Auckl). 2022;12:1–14.
The authors have advised that there is an error in Table 1 on page 2. The text “IL-7A” in the Target column for the Ixekizumab row should read “IL-17A”.
The authors apologize for this error.
© 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.